Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
April 5, 2018
Rockwell Medical Announces Triferic Presentations at the 2018 National Kidney Foundation Spring Clinical Meetings
WIXOM, Mich., April 05, 2018 (GLOBE NEWSWIRE) --  Rockwell Medical, Inc. (RMTI), announced today that three Triferic abstracts have been selected for presentation at the National ...
April 4, 2018
Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors
INGELHEIM, Germany and NANTES, France, April 04, 2018 (GLOBE NEWSWIRE) -- Boehringer Ingelheim and OSE Immunotherapeutics (Mnémo:OSE), a biotechnology company focused on the development of ...
April 4, 2018
Paratek’s New Drug Applications for Oral and Intravenous Omadacycline Accepted for Priority Review by FDA
BOSTON, April 04, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (PRTK) announced today that the U.S. Food and Drug Administration (FDA) has accepted the New ...
April 4, 2018
Windtree Therapeutics Announces Closing of $2.6 Million Private Placement
WARRINGTON, Pa., April 4, 2018 /PRNewswire/ -- Windtree Therapeutics, Inc. (WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today announced that it ...
April 4, 2018
Eleven Biotherapeutics Reports Fourth Quarter and Full-Year 2017 Operating Results and Vicinium Development Progress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eleven Biotherapeutics, Inc. (EBIO), a late-stage clinical company developing next-generation antibody-drug conjugate (ADC) therapies for the treatment of cancer, today reported key pipeline ...
April 4, 2018
Conatus Pharmaceuticals Announces Top-line Results from Phase 2b POLT-HCV-SVR Clinical Trial
SAN DIEGO, April 04, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (CNAT), a biotechnology company focused on the development of novel medicines to treat liver ...
April 4, 2018
Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors
INGELHEIM, Germany and NANTES, France, April 04, 2018 (GLOBE NEWSWIRE) -- Boehringer Ingelheim and OSE Immunotherapeutics (Mnémo:OSE), a biotechnology company focused on the development of ...
April 4, 2018
EDAP TMS SA : EDAP Reports First US Cohort Study Results of Focal HIFU Prostate Ablation Shows Promising Outcomes
LYON, FRANCE, AUSTIN, TX -- APRIL 3, 2018 - EDAP TMS (EDAP) today announced that preliminary results of the first U.S. clinical cohort study of ...
April 4, 2018
CytoSorbents Refinances Existing Debt with New $15 Million Debt Facility with Bridge Bank
MONMOUTH JUNCTION, N.J., April 4, 2018 /PRNewswire/ -- CytoSorbents Corporation(CTSO), a critical care immunotherapy leader using CytoSorb® blood purification to treat deadly inflammation in critically-ill and ...
April 4, 2018
Mustang Bio to Present at Biotech Innovations Conference
NEW YORK, April 04, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (MBIO), a Fortress Biotech (FBIO) Company focused on the development of novel immunotherapies ...
April 4, 2018
Intec Pharma Announces Poster Presentation at American Academy of Neurology Annual Meeting
JERUSALEM, April 4, 2018 /PRNewswire/ -- Intec Pharma LTD (NTEC) (NTEC) ("Intec" or "the Company") today announces that data collected from the Company's Phase 2 development ...
April 3, 2018
ProQR to Present at Two Upcoming Conferences
LEIDEN, the Netherlands, April 03, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA ...
April 3, 2018
Palatin Technologies Presents Preclinical Oral Formulation Data on PL-8177, An Investigational Melanocortin Receptor 1 Agonist for Inflammatory Bowel Diseases
CRANBURY, N.J., April 3, 2018 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of ...
April 3, 2018
Reata to Present Preclinical Data on RTA 1701, a Novel RORγt Inverse Agonist, at Upcoming Immunology Conference
IRVING, Texas, April 03, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (RETA) (Reata or Company), a clinical-stage biopharmaceutical company, today announced the upcoming presentation of ...
April 3, 2018
Aptose to Present at the H.C. Wainwright Annual Global Life Sciences Conference
SAN DIEGO and TORONTO, April 03, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (APTO) (APS.TO), a clinical-stage company developing highly differentiated ...
April 3, 2018
HTG Announces New Patent for Its Technology Issued in Japan
TUCSON, Ariz., April 03, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today ...
April 3, 2018
ARMO BioSciences to Participate in Panel on Cytokines at 8th Annual Cancer Immunotherapy Conference
REDWOOD CITY, Calif., April 03, 2018 (GLOBE NEWSWIRE) -- ARMO BioSciences, Inc. (ARMO), a late-stage immuno-oncology company, today announced that Martin Oft, M.D., Senior Vice ...
April 3, 2018
Aeglea BioTherapeutics to Present New Phase 1/2 Trial Results in Arginase 1 Deficiency at the 2018 ACMG Annual Clinical Genetics Meeting
AUSTIN, Texas, April 03, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for ...
April 3, 2018
Intec Pharma Ltd. to Host Key Opinion Leader Luncheon on Novel Drug Delivery Solutions in the Treatment of Parkinson's Disease
JERUSALEM, April 3, 2018 /PRNewswire/ --Intec Pharma Ltd. (NTEC) (NTEC.TA), a clinical stage biopharmaceutical company focused on developing pharmaceutical therapies based on its proprietary Accordion ...
April 3, 2018
Bellerophon Therapeutics to Provide Corporate Update at H.C. Wainwright Annual Global Life Sciences Conference
WARREN, N.J., April 03, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that Fabian Tenenbaum, ...
Page 93 of 158